Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 October 2019
Omalizumab for treating severe persistent allergic asthma (TA278)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2013
Pharmalgen for the treatment of bee and wasp venom allergy (TA246)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 February 2012
Berotralstat for preventing acute attacks of hereditary angioedema [ID1624]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 August 2021
Palforzia for treating peanut allergy [ID1282]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 January 2022
STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC